

# We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

6,900

Open access books available

186,000

International authors and editors

200M

Downloads

Our authors are among the

154

Countries delivered to

TOP 1%

most cited scientists

12.2%

Contributors from top 500 universities



WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index  
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?  
Contact [book.department@intechopen.com](mailto:book.department@intechopen.com)

Numbers displayed above are based on latest data collected.  
For more information visit [www.intechopen.com](http://www.intechopen.com)



# Robotic Surgery for Non-Small Cell Lung Cancer

*Andrew X. Li and Justin D. Blasberg*

## Abstract

Pulmonary resection has been a cornerstone in the management of patients with non-small cell lung cancer (NSCLC) for decades. In recent years, the popularity of minimally-invasive techniques as the primary method to manage NSCLC has grown significantly. With smaller incisions and a lower incidence of peri-operative complications, minimally-invasive lung resection, accomplished through keyhole incisions with miniaturized cameras and similarly small instruments that work through surgical ports, has been shown to retain equivalent oncologic outcomes to the traditional gold standard open thoracotomy. This technique allows for the safe performance of anatomic lung resection with complete lymphadenectomy and has been a part of thoracic surgery practice for three decades. Robotic-assisted thoracoscopic surgery (RATS) represents another major advancement for lung resection, broadening the opportunity for patients to undergo minimally invasive surgery for NSCLC, and therefore allowing a greater percentage of the lung cancer population to benefit from many of the advantages previously demonstrated from video assisted thoracoscopic surgery (VATS) techniques. RATS surgery is also associated with several technical advantages to the surgeon. For a surgeon who performs open procedures and is looking to adopt a minimally invasive approach, RATS ergonomics are a natural transition compared to VATS, particularly given the multiple degrees of freedom associated with robotic articulating instruments. As a result, this platform has been adopted as a primary approach in numerous institutions across the United States. In this chapter, we will explore the advantages and disadvantages of robotic-assisted surgery for NSCLC and discuss the implications for increased adoption of minimally invasive surgery in the future of lung cancer treatment.

**Keywords:** non-small cell lung cancer, pulmonary resection, minimally invasive surgery, robotic surgery, robotic-assisted thoracoscopic surgery

## 1. Introduction

Surgical resection for early stage non-small cell lung cancer (NSCLC) (Stage I and II) is associated with the lowest risk for local and distant recurrence and the best 5-year survival compared to other available treatment options [1]. The preferred approach for the surgical management of resectable, early-stage NSCLC has shifted in recent years from open thoracotomy to minimally-invasive surgery (MIS). Although thoracotomy has evolved over several decades to utilize muscle sparing incisions and improved postoperative pain control using epidural and paravertebral catheter systems, this technique is associated with more significant muscle

dissection, rib spreading, and increased risk for morbidity and mortality after surgery. This includes a protracted period of recovery following hospital discharge, a slower return to baseline quality of life, and the potential for chronic pain associated with a larger thoracotomy incision.

With fewer perioperative complications and quicker recovery, minimally invasive surgery offers expanded opportunities for surgical resection in patients who otherwise would not tolerate the morbidity of thoracotomy. There are additional benefits to minimally invasive resection, including significantly improved postoperative pain control, shorter hospital length of stay, quicker return to baseline quality of life, and earlier return to work that enhance and support the utilization of this platform for NSCLC [2–4]. These advantages have resulted in a significant shift in the surgical management of NSCLC patients, where formerly open resection and up to a week-long hospitalization were standard even without significant postoperative complications, current expectations for VATS lung resection include discharge to home in the majority of cases within 4–5 days or less [5]. Additionally, in cases where there may be a recommendation for adjuvant therapy, MIS patients are more likely to have recovered and be ready to receive such therapy earlier in their treatment course. Therefore, minimally invasive resection has significant advantages, especially when considering some percentage of thoracotomy patients might not receive adjuvant therapy given a challenging recovery from their index lung resection.

Video-assisted thoracoscopic surgery (VATS) for lung resection has been a part of the thoracic surgeon's toolbox for the past three decades. Lewis et al. first described the use of VATS in 1992 [6]. The technique was quickly adapted to lobectomy in elderly patients with early-stage NSCLC, where some of the first cases were completed with similar or better results to historical controls [7]. Since these initial reports, VATS surgery has become increasingly common, with expanded use in complex lung resections, pneumonectomy, bronchovascular sleeve resections, and tumors that include the chest wall [8–10]. While only 8% of lobectomies in the United States were performed thoracoscopically in 2003, this figure has increased significantly over time, up to 54% as reported in 2014, especially among high-volume surgeons [11–13]. Trends that favor VATS adoption include being a dedicated thoracic surgeon in a high-volume center, performance of lung resection in a larger hospital, and lung resections performed in the Northeast. In one multi-variate analysis, there was a significant association between VATS adoption and surgeon volume (>15 lobectomies performed per year), which is not unexpected given the technical challenges associated with becoming proficient with this technique [11]. Although VATS adoption has significantly improved, there remains a large number of both general, dedicated thoracic, and cardiothoracic surgeons who continue to perform a thoracotomy for NSCLC, limited by both volume challenges and the learning curve associated with VATS lobectomy. Although the percentage of open lung resection has declined over time, this technique still represents a large proportion of early stage NSCLC surgery performed in the United States. As a result, there is an opportunity to expand on the availability of minimally invasive lung resection to patients, and to do so using technology that favors a natural transition for otherwise traditional open surgeons.

This need has led to another major technical innovation in thoracic surgery over the last two decades with the adoption of the Da Vinci robotic system (Intuitive Surgical Inc., Sunnyvale, CA, USA), a platform that is at the forefront of minimally-invasive lung, esophageal, and mediastinal tumor resection. In robotic-assisted thoracoscopic surgery (RATS), the surgeon is seated at a console adjacent to the sterile field which operates a bedside patient cart with several robotic arms (**Figure 1**). Attached to these arms are robotic instruments that enter the pleural space via key-hole incisions and robotic ports. At the console, the surgeon manipulates the robotic



**Figure 1.**  
*Da Vinci XI patient cart with four robotic arms. Image courtesy of © [2020] Intuitive Surgical, Inc.*

arms with three-dimensional controls which translate the surgeon's hand movements to the wristed instruments on each of the robotic arms. A RATS platform aids the surgeon by enhancing visualization with a three-dimensional high-definition view, minimizing hand tremors, and improving dexterity of the instruments by functioning with multiple degrees of freedom. Wristed instruments mimic the surgeon's actual hand movements, simulating open surgery, allowing for the precise dissection of vascular structures and a thorough lymphadenectomy, key steps to success when performing minimally invasive lung resection. While this technique is a dramatic change from either open or VATS procedures as the surgeon is not at the patient's bedside, repetition and the frequency of performing robotic cases helps one's personal comfort as they transition to RATS.

Although the technical advantages of RATS make the platform desirable, the adoption of minimally-invasive robotic surgery is associated with some challenges. While benefits such as reduced postoperative pain, decreased peri-operative morbidity, reduce risk for postoperative air leak, and shorter hospital length of stay have been described, concern over upfront investment and increased cost per operation may be considered a barrier to access. Additional training for operating room staff is required, capital investment into larger operating rooms and to modernize traditional open surgery rooms that might like technological infrastructure, as well as increased operating times impact the opportunity cost of performing other operations and can contribute to some level of adoption apprehension for hospitals that have no robotic experience. Despite any misgivings, there is clear evidence that the adoption of robotic surgery for lung resection is on the rise. In just two years, from 2010 to 2012, robotic surgery increased in popularity by 3-fold, accounting for 9.1% of lung resections annually in 2012 [14]. More recently, an estimated 17.5% of lobectomies were performed robotically in 2017 [15]. Trends in robotic adoption seem to suggest that the technical advantages associated with robotic lung resection outweigh the capital and educational investment needed to make such a program successful. What specific metrics drive robotic adoption and improve outcomes in thoracic surgery are defined in the literature. This chapter will address the advantages and disadvantages of MIS for NSCLC, including the role of robotic surgery, and discuss its future directions in this field.



## **2. Advantages of robotic-assisted and video-assisted thoracoscopic surgery**

Minimally-invasive thoracoscopic surgery, and in turn RATS, have several advantages over traditional open surgery. Compared to thoracotomy, VATS and RATS utilize small incisions to access the chest cavity, reducing peri-operative morbidity and enhancing recovery. This allows the surgeon to select a larger range of patients who may otherwise be unable to tolerate open resection. Avoiding the muscle dissection/division and rib spreading associated with thoracotomy, while not compromising on the oncologic efficacy of the procedure, are the key advantages to both VATS and RATS procedures. For the facile VATS surgeon, lung resection and complete lymphadenectomy can be accomplished with a high rate of success, low risk of complication, and an expedited pathway to recovery. There are specific subsets of patients at higher risk for conversion during VATS procedures, particularly in cases where dissection is difficult due to fibrocalcified nodes, large tumor >3 cm, or prior induction therapy [16, 17]. In these cases, the advantages of robotics can be significant. The fundamental benefit of the robotic platform is that it simulates open techniques but with the advantages of smaller incision surgery. RATS procedures utilize insufflation to help maximize exposure, 3-dimensional optics to help define important structures and their relationship to adjacent structures, 10× magnification rather to improve visualization, and the ability to reach farther into the chest with longer instruments while still performing fine dissection work, all without losing out on the ergonomics associated with open surgery. This includes the ability to use robotic stapling devices which are similar to open and VATS variants, bipolar energy devices that articulate, vessel sealing devices that articulate, and fluorescence imaging in cases where tumor localization or performance of segmental resection is preferred. Not only does this provide open-only surgeons with an easier opportunity to incorporate MIS into their technical portfolio but affords a larger number of patients with the opportunity to undergo minimally invasive lung resection when appropriate.

An additional advantage is the ease in which segmental resection can be performed. RATS visualization and the precision in which segmental anatomy can be dissected has helped improve the adoption of segmentectomy in the United States [18]. As new data becomes available regarding the advantage of segmental resection over wedge, and potentially the equivalence of segmentectomy to lobectomy for subsets of early stage NSCLC either <2 cm or in patients with non-solid nodules, the utilization of techniques to improve rates of segmentectomy will become more important. While VATS segmentectomy is both well described and widely performed, it remains a technical challenge for many surgeons to adopt with proficiency required that can be significantly more complex than superior segmentectomy. RATS segmentectomy may be an opportunity for lobectomy only surgeons to increase their success with segmentectomy given these advantages. Previously data has demonstrated that surgical outcomes are comparable between RATS and VATS segmentectomy, both in terms of oncologic outcome and the adequacy of lymph node evaluation [19]. This principle is important to keep in mind as there is no scenario in which the size of an incision is more important than achieving an appropriate and adequate lung cancer resection.

### **2.1 Patient selection**

MIS allows surgeons to select patients who would otherwise be unable to tolerate open pulmonary resection. The morbidity of a thoracotomy precludes many patients from benefitting from surgery with otherwise resectable cancers, leading

to suboptimal treatments and decreased survival. In these cases, some institutions may turn to a more liberal use of radiation therapy as a means of local control. However, many studies have demonstrated the increased risk of local recurrence and inferior 5-year survival that makes radiation a less desirable choice for subsets of NSCLC patients, even in early stage cancers [1, 20, 21]. The decision to pursue surgery and in what format requires clinical judgment and cannot be determined by looking at one particular clinical parameter (ex. FEV1/DLCO, performance status, specific comorbidities alone). For example, a patient with less than perfect but acceptable pulmonary reserve, a history of cardiac disease who is medically optimized with a negative stress test, and in a motivated patient with reasonable performance status, surgical resection is likely to be well tolerated and preferable to other local therapy options (ex. SBRT or ablation). In this subset, MIS has obvious benefits compared to open resection. For example, in patients who underwent minimally-invasive thoroscopic surgery, preoperative FEV1 < 60% was noted to be significantly associated with a lower risk for postoperative complications compared to thoracotomy patients [12]. Although this concept may have seemed novel at the time, there is clearly an association between postoperative pain control, patient ambulation and participation with pulmonary toilet, and risk for postoperative complications following lung resection. Therefore, in patients who might be viewed as medically more marginal, MIS provides these patients with an opportunity for a curative resection and the benefits of lung cancer survival identified in the lung cancer study group with a lower complication profile [22].

Elderly patients are also at risk of receiving suboptimal treatment due to a perception of high-risk associated with surgery. When evaluating the surgical candidacy of this group, it is critical to determine both: 1) preoperative cardiac fitness and performance status as well as 2) competing causes of death. In the current era, it is reasonable to consider MIS as a curative procedure for early stage NSCLC in patients in their 80's or even in their 90's. Without a competing cause of death, it is reasonable to consider surgical resection for early-stage NSCLC in this age group. However, thoracotomy is a physiologically demanding procedure, and in elderly patients, MIS should be strongly considered when possible. Previous reports have demonstrated that post-operative outcomes remain superior in RATS and VATS compared to open thoracotomy for elderly patients. One propensity score-adjusted analysis examining 2,766 patients over the age of 65 with stage I to IIIa NSCLC in the Surveillance, Epidemiology, and End Results (SEER)-Medicare database found lower overall surgical complication rates in RATS versus thoracotomy, as well as lower rates of blood transfusion, shorter ICU stay, and a significant decrease in overall length of stay [23]. In the same study, both VATS and RATS were found to have lower complication rates, adequate lymph node evaluation, and equivalent lung cancer specific survival [23].

Obese patients pose unique challenges for thoracic surgery. While studies show obese patients may have similar risk for complications and long-term outcomes compared to patients with normal body mass index (BMI), severely overweight patients (BMI greater than or equal to 40 kg/m<sup>2</sup>) face an increased risk of any major postoperative complication, including atelectasis requiring bronchoscopy, pneumonia, ARDS, extended ventilatory support, reintubation, and tracheostomy [24]. In addition to consideration for postoperative pain control, adequate pulmonary toilet, the ability to transfer patients from bed to chair, and the need for postoperative patients to ambulate aggressively, a question that arises is an obese patient's tolerability of a longer surgical case. This may be even more important when for RATS lung resection, especially for surgeons early in their learning curve where operative times may be longer than VATS procedures. When we look to literature and evaluate best available data to help develop a recommendation, the use of RATS in obese

patients has not been shown to be associated with a significantly higher risk of postoperative complications, longer hospital length-of-stay (LOS), and is associated with similar 5-year survival compared to open lobectomy, suggesting that a robotic approach remains safe in this patient population [25]. While the outcomes of RATS lung resection in the obese population may be similar to VATS, the technical advantages of performing an anatomic lung resection in this population remain significant. To date, no large database or single institution data has defined an association between BMI and inferior outcomes in obese patients that require conversion due to vascular injury or technical challenges associated with lung resection.

## **2.2 Perioperative complications**

Patients undergoing RATS experience a similar or lower rate of perioperative complications compared to those who undergo open thoracotomy or VATS. Post-operative complications after robotic lung resection were seen in 10–39% of patients in a review which included five case series and four comparative studies [26]. The most common postoperative complications included prolonged air leaks and atrial fibrillation [26, 27]. Pooled analysis of several studies did not show a prolonged air leak risk that was significantly higher following robotic surgery compared to thoracotomy [28].

Major complications including acute respiratory distress, reoperation for air leak, pulmonary embolism, or arrhythmia requiring pacemaker placement were rare, seen in approximately 2.4% of patients [27]. The rate of major complication in robotic surgery appears lower than thoracotomy, with fewer instances of respiratory failure, hemorrhage, or reoperation [29, 30]. Currently, perioperative mortality at high volume centers where most robotic surgeries are performed is lower in RATS compared to open resection [31]. Although this outcome metric is difficult to interpret as mortality is low for all lung resection regardless of surgical technique, it should be expected that as more centers adopt robotics for minimally invasive resection, the morbidity and mortality of RATS should remain at a comparable level to open and VATS resection.

Conversion from RATS to an open procedure is also low. Recent studies demonstrated a conversion rate of 6.5–9.2% [27, 29, 32]. The most common indications for conversion were technical limitations, inability to achieve an adequate oncologic resection, and bleeding [27]. The learning curve for RATS proficiency appears to be in the range of 20–25 cases, after which the risk for conversion can be expected to go down significantly. Unlike VATS conversions, where the surgeon is present at the bedside and can more easily perform a thoracotomy expeditiously, RATS conversions require a coordinated and well planned ‘fire drill’ to ensure patient safety. This includes a bedside assist that can hold pressure on a bleeding structure via a non-robot port, that the robot arms can be moved away to allow for better access to the chest, and that the staff in the room are prepared to open instruments that are needed to complete the case. Although these processes may be unfamiliar to the novice robotic surgeon, adequate preparation for case should include discussion of these scenarios with the operating and anesthesia staff. When compared to VATS, there were no differences in conversion rates in recent independent studies or meta-analyses [28, 29].

Robotic surgery holds several key advantages with regards to post-operative outcomes when directly comparing VATS and RATS techniques. In one retrospective propensity score-matched study of 774 patients undergoing anatomical segmentectomy at a single academic institution, there were no significant differences in operative time, blood loss, risk for postoperative complication, or length of stay between RATS and VATS [33]. In another study examining 50 RATS and 80 VATS



segmentectomies for patients with stage IA lung cancer at the Shanghai Chest Hospital, there was a shorter mean operative time and lower blood loss with RATS during anatomic resection and mediastinal lymphadenectomy [34]. For centrally located tumors which may be more difficult to access through VATS, robotic surgery was found to be associated with less bleeding, shorter operative times, and reduced volume of chest tube drainage and days with a chest tube, while having comparable oncologic outcomes including disease-free survival [35]. In a meta-analysis of ten studies by Emmert examining perioperative outcomes of minimally invasive thoracic surgery, tube drainage duration, length of hospitalization, and mortality were lower in patients undergoing RATS compared to VATS [36]. Therefore, it is reasonable to consider that the technical advantages associated with the robotic platform, including enhanced visualization and use of articulating instruments, are responsible for the low complication rates seen in RATS lung resection, and that with proficiency the outcomes of this technique can be equivalent to VATS.

### **2.3 Patient outcomes**

One important area of scrutiny associated with the adoption of robotic surgery has been that VATS outcomes are already significantly better than open surgery, and that an expensive minimally invasive alternative with surgeon only advantages is a challenge to justify. As with any new technology, are the important outcomes the same or better? This is a fundamental necessity in cancer surgery. These concerns have been expressed since the introduction of the first robot in 2001, particularly with respect to adoption of both VATS and RATS approaches. When studied well, it is clear that both VATS and RATS are associated with excellent oncologic outcomes, equivalent to open surgery particularly with respect to lymph node evaluation and adequacy of resection, and that depending on the platform chosen, a proficient surgeon can be expected to have outcomes that meet or exceed their open surgery experience.

Several studies have examined and compared margin status, recurrence, disease-specific survival, and overall survival in open thoracotomy, VATS, and RATS. A study of the National Cancer Database found similar positive margin status (2%) after robotic surgery as compared to open resection, which is considerable given the lack of haptic feedback associated with RATS [37]. Other series also describe similar R0 resection rates of 97% [38]. Five-year disease recurrence has reported to be from 3% to 24.9% depending on cancer stage, which is also comparable to open surgery for appropriately matched patients [32, 39]. In this series and others, overall and disease-free survival at three and five years did not differ between RATS and either open surgery or VATS [32, 37, 38, 40–43]. These results all suggest that robotic lung resection is a non-inferior alternative to prior surgical options.

The data on nodal evaluation during lung resection is heterogeneous for robotic surgery. Some studies report no advantage in nodal stations examined or nodal harvest when compared to open surgery or VATS [28, 29, 44, 45]. One study found that fewer lymph nodes were examined with RATS compared to VATS [14]. Others report improved lymph node examination and retrieval [30, 33, 37, 46, 47]. In particular, one study found N1 (hilar) lymph nodes were better evaluated by robotic surgery as compared to VATS, both in terms of the number (4 vs. 3) and stations (3 vs. 2) examined [33]. The experience of these authors and others are that the technical advantages of robotic surgery allow for an equivalent lymph node dissection to VATS, with some significant advantages including improved hemostasis and thoroughness of lymph node resection performed during mediastinal lymphadenectomy. The use of articulating bipolar instruments allows for complete lymph node packet resection, while improved visualization helps to define lymph node



associations to adjacent structures. This is clearly an advantage over VATS, where ring clamps or non-articulating instruments can be used to grasp lymph nodes and non-articulating energy devices are used to free lymph nodes from surrounding structures. Whether these technical advantages translate into differences in short or long-term outcomes is unknown. However, no study to date has demonstrated that taking fewer lymph nodes or an incomplete lymph node evaluation is better than comprehensive lymphadenectomy. Additionally, as surgical outcomes become more heavily scrutinized, particularly with respect to the adequacy of lymph node dissection, the use of this platform is likely to help facilitate a comprehensive hilar and mediastinal lymphadenectomy to meet these expectations.

## **2.4 Technical considerations**

The true advantage of robotic surgery appears to be the technical advantages conferred to the surgeon, specifically the enhanced visualization and improved dexterity of the instruments. While comparisons between robotic and open thoracotomy appear to have similar rates of complications, outcomes of VATS versus RATS are less uniform. Robotic surgery, in some series, is associated with less bleeding, shorter operative time, and shorter tube drainage duration [35]. These studies are largely retrospective and do not offer a definitive answer as to the causation for these improvements. However, one factor that likely contributes to these perceived results are the ergonomics of the robotic system. Robotic instruments moved with seven degrees of freedom, and as a result the surgeon in control at the console can mimic natural motions of the hand and wrist in the handling of tissue. This allows a surgeon to perform more complex functions in a safer fashion, reducing the risk of inadvertent injury while maintaining the oncologic standards. Important moves during anatomic lung resection, including thorough performance of lymphadenectomy and circumferential mobilization of critical vascular structures, can be performed with improved hemostasis, improved visualization, and reduced risk of injury.

## **2.5 Conclusions**

Overall, the literature supports RATS as an alternative to open surgery and VATS. Fewer perioperative complications, improved quality of life, and similar oncologic outcomes have been established following RATS lung resection, bringing minimally invasive surgical options to a wider range of patients. While the advantages of RATS over VATS are certainly up for debate and are more informed by surgeon preference, the ability to improve minimally invasive lung resection availability to patients across the United States helps to drive interest in outcomes related to RATS procedures. The literature clearly demonstrates that surgeons facile with VATS lung resection provide patients with an oncologically sound operation and survival/recurrence expectations that rival results demonstrated in the LCSG. However, this skillset is challenging to learn and the highest standards for technical excellence are not as reproducible as open surgical techniques. In this space, RATS lung resection continues to evolve as adoption of minimally invasive lung resection grows.

## **3. What makes robotic surgery adoption different than VATS?**

While robotic surgery has key advantages compared to open and VATS techniques, it has not been uniformly adopted. As compared to VATS, this technology requires a significant capital investment, is associated with its own learning curve, and requires robotically trained support staff for a surgeon to have a successful robotic lung

resection practice. All of these characteristics can be overcome but require stakeholders from surgery and the operating room to commit to the success of this platform.

### **3.1 Cost**

The cost of robotic surgery is one of its main points of contention. There are two aspects of robotic surgery which contribute to this cost. The first is the initial investment in the robotic system. The second includes intra-operative costs, consisting of the use of consumables and longer operative times associated with RATS [28, 33, 45]. As the second is modifiable, it has garnered more attention in the literature. One study using patients from the SEER-Medicare database found the total cost of lung resection was similar between RATS and thoracotomy (\$54,702 vs. \$57,104,  $p = 0.08$ ) [23]. Much of the variability in cost associated with robotic surgery likely stems from the difference in post-operative complications when compared to open resection. In particular, overall length of stay after RATS is significantly shorter than open surgery [29, 31, 38, 47, 48], and may be similar or better than VATS (4 days vs. 5 days) [40]. Therefore, although the cost of the operation may be higher in RATS, the direct associated cost may not be significantly different compared to open or VATS [49]. In time, as familiarity with the robotic platform increases and operating room efficacy is improved to rival VATS procedures, further cost savings can offset the increased initial investment and operative costs.

### **3.2 Learning curve**

Another concern for surgeons unfamiliar with robotic surgery is training and familiarization with a new surgical platform. In fact, one of the early difficulties with the transition from VATS to open surgery was the steep learning curve. Laparoscopic instruments are relatively inflexible compared to the dexterity a surgeon is accustomed to during open surgery. Circumferential mobilization of important blood vessels requires dissection facilitated by subtle changes in how one engages the tissue, and these techniques are both important and challenging to learn for a novice VATS surgeon. Additionally, the VATS camera is limited to 3.5x magnification, images are shown in only 2 dimensions, and the camera needs to be held and constantly adjusted by the surgeon assistant. At 10x magnification, with 3D imaging, and a fixed camera that is not subject to fatigue or the concept of 'guess what I am thinking and look where I want you to look', getting used to robotic optics is fairly quick. The learning curve for a robotic lobectomy is approximately twenty cases [26, 50]. In this regard, mastery of robotic surgery appears to be easier than VATS, owing to the more natural movements afforded by the robot.

Efficiency of RATS does rely more heavily on the familiarity of supporting operating room staff and the surgeon's bedside assistant than VATS procedures. As the surgeon is seated at a console away from the sterile field, a bedside assistant must assist in exchanging instruments and repositioning robotic arms as needed. Thus, in addition to surgeon training, it is imperative that adequate training be provided to dedicated staff supporting the surgeon in order to maintain a safe working environment and maximum efficiency.

### **3.3 Choosing robotic surgery**

In our experience, a surgeon who gains robotic proficiency prefers the robot for a majority of their cases unless the platform is unavailable. Technically, VATS offers little advantage over RATS for the operating surgeon. Few instances exist where cost and time to set up outweighs the benefit. We utilize VATS for short cases such

as decortications and pleurodesis, but favor RATS for most pulmonary resections. For technically challenging cases such as pneumonectomies, open surgery may be preferred, however, some case series describe successful RATS applications in pneumonectomy [51, 52].

#### **4. Conclusions**

In conclusion, robotic surgery represents the latest innovation for lung cancer surgery and an important opportunity for general and thoracic surgeons who still perform open lung resection. RATS procedures are associated with comparable or better outcomes than open surgery or VATS, and over the past two decades has been shown to be a safe platform with which lung cancer procedures can be performed. RATS procedures have significant technical advantages for the surgeon, namely the 3D vision, 10× magnification, and articulating instruments that mimics open surgery and allows for the performance of critical components of an operation safely. Although the advantages of RATS for patients are similar to VATS procedures, the adoption of RATS by open surgeons allows for a larger number of lung cancer patients in the United States to undergo minimally invasive procedures than ever before, which further realizes the patient specific advantages of minimally invasive techniques in this often medically complex population. A lower complication rate and better tolerability increases access to a definitive resection for NSCLC, optimizing 5-year survival. In time, as the volume of robotic surgery increases, the capital investment associated with adoption is likely to decrease. Additionally, with increased surgeon experience, operative times, risks for air leak, and overall hospital length of stay are also expected to decrease, allowing for improved utilization of hospital resources and efficiency.

#### **Conflict of interest**

Justin D. Blasberg, MD MPH is a proctor for Intuitive Surgical.

#### **Notes/thanks/other declarations**


None.

#### **Author details**

Andrew X. Li and Justin D. Blasberg\*  
Section of Thoracic Surgery, Department of Surgery, Yale School of Medicine,  
New Haven, Connecticut, United States of America

\*Address all correspondence to: [justin.blasberg@yale.edu](mailto:justin.blasberg@yale.edu)

#### **IntechOpen**

© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/3.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 

## References

- [1] Cornwell LD, Echeverria AE, Samuelian J, Mayor J, Casal RF, Bakaeen FG, et al. Video-assisted thoracoscopic lobectomy is associated with greater recurrence-free survival than stereotactic body radiotherapy for clinical stage I lung cancer. *J Thorac Cardiovasc Surg.* 2018;155(1):395-402.
- [2] Hristov B, Eguchi T, Bains S, Dycoco J, Tan KS, Isbell JM, et al. Minimally Invasive Lobectomy Is Associated With Lower Noncancer-specific Mortality in Elderly Patients: A Propensity Score Matched Competing Risks Analysis. *Ann Surg.* 2019;270(6):1161-1169.
- [3] Kumar A, Deng J, Raman V, Okusanya O, Baiu I, Berry MF, et al. A National Analysis of Minimally Invasive vs Open Segmentectomy for Stage IA Non-small-cell Lung Cancer. *Semin Thorac Cardiovasc Surg.* 2020.
- [4] Gaudet MA, D'Amico TA. Thoracoscopic Lobectomy for Non-small Cell Lung Cancer. *Surg Oncol Clin N Am.* 2016;25(3):503-513.
- [5] Nachira D, Meacci E, Margaritora S, Ismail M. Level of evidence on long-term results after VATS lobectomy: state of the art. *J Thorac Dis.* 2019;11(6):2192-2194.
- [6] Lewis RJ, Caccavale RJ, Sisler GE, Mackenzie JW. One hundred consecutive patients undergoing video-assisted thoracic operations. *Ann Thorac Surg.* 1992;54(3):421-426.
- [7] McKenna RJ, Jr. Thoracoscopic lobectomy with mediastinal sampling in 80-year-old patients. *Chest.* 1994;106(6):1902-1904.
- [8] Nagai S, Imanishi N, Matsuoka T, Matsuoka K, Ueda M, Miyamoto Y. Video-assisted thoracoscopic pneumonectomy: retrospective outcome analysis of 47 consecutive patients. *Ann Thorac Surg.* 2014;97(6):1908-1913.
- [9] Xie D, Deng J, Gonzalez-Rivas D, Zhu Y, Jiang L, Jiang G, et al. Comparison of video-assisted thoracoscopic surgery with thoracotomy in bronchial sleeve lobectomy for centrally located non-small cell lung cancer. *The Journal of Thoracic and Cardiovascular Surgery.* 2020.
- [10] Dal Agnol G, Oliveira R, Ugalde PA. Video-assisted thoracoscopic surgery lobectomy with chest wall resection. *J Thorac Dis.* 2018;10(Suppl 22):S2656-S2S63.
- [11] Blasberg JD, Seder CW, Levenson G, Shan Y, Maloney JD, Macke RA. Video-Assisted Thoracoscopic Lobectomy for Lung Cancer: Current Practice Patterns and Predictors of Adoption. *Ann Thorac Surg.* 2016;102(6):1854-1862.
- [12] Ceppa DP, Kosinski AS, Berry MF, Tong BC, Harpole DH, Mitchell JD, et al. Thoracoscopic lobectomy has increasing benefit in patients with poor pulmonary function: a Society of Thoracic Surgeons Database analysis. *Ann Surg.* 2012;256(3):487-493.
- [13] Phillips JD, Bostock IC, Hasson RM, Goodney PP, Goodman DC, Millington TM, et al. National practice trends for the surgical management of lung cancer in the CMS population: an atlas of care. *J Thorac Dis.* 2019;11(Suppl 4):S500-S5S8.
- [14] Rajaram R, Mohanty S, Bentrem DJ, Pavey ES, Odell DD, Bharat A, et al. Nationwide Assessment of Robotic Lobectomy for Non-Small Cell Lung Cancer. *Ann Thorac Surg.* 2017;103(4):1092-1100.
- [15] Wightman SC, Lui NS. Overview of robotic surgery for lung cancer. *Video-Assisted Thoracic Surgery.* 2020;5.



- [16] Augustin F, Maier HT, Weissenbacher A, Ng C, Lucciarini P, Öfner D, et al. Causes, predictors and consequences of conversion from VATS to open lung lobectomy. *Surg Endosc*. 2016;30(6):2415-2421.
- [17] Byun CS, Lee S, Kim DJ, Lee JG, Lee CY, Jung I, et al. Analysis of Unexpected Conversion to Thoracotomy During Thoracoscopic Lobectomy in Lung Cancer. *Ann Thorac Surg*. 2015;100(3):968-973.
- [18] Perroni G, Veronesi G. Robotic segmentectomy: indication and technique. *Journal of Thoracic Disease*. 2020;12(6):3404-3410.
- [19] Liang H, Liang W, Zhao L, Chen D, Zhang J, Zhang Y, et al. Robotic Versus Video-assisted Lobectomy/Segmentectomy for Lung Cancer: A Meta-analysis. *Ann Surg*. 2018;268(2):254-259.
- [20] Bryant AK, Mundt RC, Sandhu AP, Urbanic JJ, Sharabi AB, Gupta S, et al. Stereotactic Body Radiation Therapy Versus Surgery for Early Lung Cancer Among US Veterans. *Ann Thorac Surg*. 2018;105(2):425-431.
- [21] Shirvani SM, Jiang J, Chang JY, Welsh J, Likhacheva A, Buchholz TA, et al. Lobectomy, sublobar resection, and stereotactic ablative radiotherapy for early-stage non-small cell lung cancers in the elderly. *JAMA Surg*. 2014;149(12):1244-1253.
- [22] Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. *Ann Thorac Surg*. 1995;60(3):615-622; discussion 22-3.
- [23] Veluswamy RR, Whittaker Brown SA, Mhango G, Sigel K, Nicastrì DG, Smith CB, et al. Comparative Effectiveness of Robotic-Assisted Surgery for Resectable Lung Cancer in Older Patients. *Chest*. 2020;157(5):1313-1321.
- [24] Williams T, Gulack BC, Kim S, Fernandez FG, Ferguson MK. Operative Risk for Major Lung Resection Increases at Extremes of Body Mass Index. *Ann Thorac Surg*. 2017;103(1):296-302.
- [25] Casiraghi M, Sedda G, Diotti C, Mariolo AV, Galetta D, Tessitore A, et al. Postoperative outcomes of robotic-assisted lobectomy in obese patients with non-small-cell lung cancer. *Interact Cardiovasc Thorac Surg*. 2020;30(3):359-365.
- [26] Louie BE. Robotic lobectomy for non-small cell lung cancer. *Indian J Surg Oncol*. 2013;4(2):125-131.
- [27] Casiraghi M, Galetta D, Borri A, Tessitore A, Romano R, Diotti C, et al. Ten Years' Experience in Robotic-Assisted Thoracic Surgery for Early Stage Lung Cancer. *Thorac Cardiovasc Surg*. 2019;67(7):564-572.
- [28] Guo F, Ma D, Li S. Compare the prognosis of Da Vinci robot-assisted thoracic surgery (RATS) with video-assisted thoracic surgery (VATS) for non-small cell lung cancer: A Meta-analysis. *Medicine (Baltimore)*. 2019;98(39):e17089.
- [29] Kneuert PJ, D'Souza DM, Richardson M, Abdel-Rasoul M, Moffatt-Bruce SD, Merritt RE. Long-Term Oncologic Outcomes After Robotic Lobectomy for Early-stage Non-Small-cell Lung Cancer Versus Video-assisted Thoracoscopic and Open Thoracotomy Approach. *Clin Lung Cancer*. 2020;21(3):214-224 e2.
- [30] Nelson DB, Mehran RJ, Mitchell KG, Rajaram R, Correa AM, Bassett RL, Jr., et al. Robotic-Assisted Lobectomy for Non-Small Cell Lung Cancer: A Comprehensive Institutional

Experience. *Ann Thorac Surg.* 2019;108(2):370-376.

Lung Cancer. *Ann Thorac Surg.* 2020;110(2):424-433.

[31] Tchouta LN, Park HS, Boffa DJ, Blasberg JD, Detterbeck FC, Kim AW. Hospital Volume and Outcomes of Robot-Assisted Lobectomies. *Chest.* 2017;151(2):329-339.

[38] Park BJ, Yang HX, Woo KM, Sima CS. Minimally invasive (robotic assisted thoracic surgery and video-assisted thoracic surgery) lobectomy for the treatment of locally advanced non-small cell lung cancer. *J Thorac Dis.* 2016;8(Suppl 4):S406–S413.

[32] Cerfolio RJ, Ghanim AF, Dylewski M, Veronesi G, Spaggiari L, Park BJ. The long-term survival of robotic lobectomy for non-small cell lung cancer: A multi-institutional study. *J Thorac Cardiovasc Surg.* 2018;155(2):778-786.

[39] Spaggiari L, Sedda G, Maisonneuve P, Tessitore A, Casiraghi M, Petrella F, et al. A Brief Report on Survival After Robotic Lobectomy for Early-Stage Lung Cancer. *J Thorac Oncol.* 2019;14(12):2176-2180.

[33] Zhang Y, Chen C, Hu J, Han Y, Huang M, Xiang J, et al. Early outcomes of robotic versus thoracoscopic segmentectomy for early-stage lung cancer: A multi-institutional propensity score-matched analysis. *J Thorac Cardiovasc Surg.* 2020.

[40] Li C, Hu Y, Huang J, Li J, Jiang L, Lin H, et al. Comparison of robotic-assisted lobectomy with video-assisted thoracic surgery for stage IIB-IIIA non-small cell lung cancer. *Transl Lung Cancer Res.* 2019;8(6):820-828.

[34] Zhou Q, Huang J, Pan F, Li J, Liu Y, Hou Y, et al. Operative outcomes and long-term survival of robotic-assisted segmentectomy for stage IA lung cancer compared with video-assisted thoracoscopic segmentectomy. *Transl Lung Cancer Res.* 2020;9(2):306-315.

[41] Sesti J, Langan RC, Bell J, Nguyen A, Turner AL, Hilden P, et al. A Comparative Analysis of Long-Term Survival of Robotic Versus Thoracoscopic Lobectomy. *Ann Thorac Surg.* 2020;110(4):1139-1146.

[35] Qiu T, Zhao Y, Xuan Y, Qin Y, Niu Z, Shen Y, et al. Robotic sleeve lobectomy for centrally located non-small cell lung cancer: A propensity score-weighted comparison with thoracoscopic and open surgery. *J Thorac Cardiovasc Surg.* 2020;160(3):838-46 e2.

[42] Turner SR, Latif MJ, Park BJ. Robotic assisted VATS lobectomy for loco-regionally advanced non-small cell lung cancer. *Video Assist Thorac Surg.* 2017;2.

[36] Emmert A, Straube C, Buentzel J, Roever C. Robotic versus thoracoscopic lung resection: A systematic review and meta-analysis. *Medicine.* 2017;96(35):e7633-e.

[43] Yang HX, Woo KM, Sima CS, Bains MS, Adusumilli PS, Huang J, et al. Long-term Survival Based on the Surgical Approach to Lobectomy For Clinical Stage I Nonsmall Cell Lung Cancer: Comparison of Robotic, Video-assisted Thoracic Surgery, and Thoracotomy Lobectomy. *Ann Surg.* 2017;265(2):431-437.

[37] Tang A, Raja S, Bribriescio AC, Raymond DP, Sudarshan M, Murthy SC, et al. Robotic Approach Offers Similar Nodal Upstaging to Open Lobectomy for Clinical Stage I Non-small Cell

[44] Louie BE, Farivar AS, Aye RW, Vallières E. Early experience with robotic lung resection results in similar operative outcomes and morbidity when

- compared with matched video-assisted thoracoscopic surgery cases. *Ann Thorac Surg.* 2012;93(5):1598-1604; discussion 604-5.
- [45] Louie BE, Wilson JL, Kim S, Cerfolio RJ, Park BJ, Farivar AS, et al. Comparison of Video-Assisted Thoracoscopic Surgery and Robotic Approaches for Clinical Stage I and Stage II Non-Small Cell Lung Cancer Using The Society of Thoracic Surgeons Database. *Ann Thorac Surg.* 2016;102(3):917-924.
- [46] Li JT, Liu PY, Huang J, Lu PJ, Lin H, Zhou QJ, et al. Perioperative outcomes of radical lobectomies using robotic-assisted thoracoscopic technique vs. video-assisted thoracoscopic technique: retrospective study of 1,075 consecutive p-stage I non-small cell lung cancer cases. *J Thorac Dis.* 2019;11(3):882-891.
- [47] Novellis P, Bottoni E, Voulaz E, Cariboni U, Testori A, Bertolaccini L, et al. Robotic surgery, video-assisted thoracic surgery, and open surgery for early stage lung cancer: comparison of costs and outcomes at a single institute. *J Thorac Dis.* 2018;10(2):790-798.
- [48] Lazar JF, Spier LN, Hartman AR, Lazzaro RS. Standardizing Robotic Lobectomy: Feasibility and Safety in 128 Consecutive Lobectomies Within a Single Healthcare System. *Innovations (Phila).* 2017;12(2):77-81.
- [49] Kneuert PJ, Singer E, D'Souza DM, Abdel-Rasoul M, Moffatt-Bruce SD, Merritt RE. Hospital cost and clinical effectiveness of robotic-assisted versus video-assisted thoracoscopic and open lobectomy: A propensity score-weighted comparison. *J Thorac Cardiovasc Surg.* 2019;157(5):2018-2026 e2.
- [50] Lee EC, Lazzaro RS, Glassman LR, Singh VA, Jurado JE, Hyman KM, et al. Switching from Thoracoscopic to Robotic Platform for Lobectomy: Report of Learning Curve and Outcome. *Innovations (Phila).* 2020;15(3):235-242.
- [51] Spaggiari L, Galetta D. Pneumonectomy for Lung Cancer: A Further Step in Minimally Invasive Surgery. *The Annals of Thoracic Surgery.* 2011;91(3).
- [52] Louie BE. Robotic Pneumonectomy. *Thoracic Surgery Clinics.* 2014;24(2):169-175.